Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer

Background: To investigate the effect of bevacizumab combined with chemotherapy on the metastasis response rate, survival time of patients with metastatic colorectal cancer (mCRC), the incidence of complications, and the efficacy and safety of bevacizumab for mCRC were recorded. Methods: Of 87 patients with mCRC, 42 were treated without bevacizumab (control group, CG) and 45 were treated with bevacizumab (observation group, OG). Baseline characteristics, resectability of metastases, quality of life (QOL), and short-and long-term curative effect were compared to evaluate the safety of the treatment plan in the two groups. Results: After 6 months of treatment, the overall response rate (ORR) and disease control rate (DCR) of the CG were 28.57% and 59.52%, respectively, whereas the ORR and DCR of the OG were notably higher at 48.89% and 86.67%, respectively (P < 0.05). The resectability rate of metastases in the OG increased from 8.89% pretreatment to 40.00% posttreatment, whereas that of metastases in the CG increased from 11.90% pretreatment to 23.81% posttreatment. In the OG, the median survival time was 23.0 (range, 19.7-26.3) months, and the median progression-free survival (PFS) was 11.0 (range, 9.4-12.6) months. These results were all superior to those of the CG, which were 14.0 (range, 12.6-15.4) months and 6.0 (range, 4.9-7.2) months, respectively. Conclusion: Bevacizumab combined with first-line chemotherapy can significantly prolong survival and PFS, improve QOL, increase the resectability rate of metastases, and improve survival outcomes of patients with mCRC.